Novo Nordisk (NVO) Tops Q4 EPS by 10c; Lowers Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Novo Nordisk (NVO) Tops Q4 EPS by 10c; Lowers Outlook
February 3, 2026 11:46 AM EST
Eli Lilly & Co. (NYSE: LLY) stock is volatile following weak guidance from rival Novo Nordisk (NYSE: NVO)
Novo Nordisk's fourth-quarter performance showed a 2% decline in sales and 4% decrease in operating profit at constant exchange rates. Sales in US Operations...
More
February 3, 2026 11:38 AM EST
Novo Nordisk reported 2025 sales growth of 10% and operating profit growth of 6% at constant exchange rates, according to a company statement. The results exceeded the Danish pharmaceutical company's previous guidance of 8% to 11% sales growth and 4% to 7% operating profit growth.
The company's fourth-quarter performance showed a 2% decline in sales and 4% decrease in operating profit at constant exchange... More
February 3, 2026 11:36 AM EST
Novo Nordisk (NYSE: NVO) Halted, News Pending
...
More
February 3, 2026 9:33 AM EST
TD Cowen analyst Michael Nedelcovych reiterated a Buy rating and $70.00 price target on Novo Nordisk (NYSE: NVO).
The analyst commented: "CagriSema First Phase III T2D Readout: Solid, But Similar To Mounjaro; Novo reported topline results for Phase III REIMAGINE 2, testing CagriSema in T2D with metformin +/- SGLT2i. At... More
